Video

Dr. Cella on Patient Reported Data's Cost Effectiveness

Author(s):

David Cella, PhD

Dr. David Cella from Northwestern University Feinberg School of Medicine on Quality of Life Assessments' Cost Effectiveness

David Cella, PhD, a clinical research specialist and chair of the Department of Medical Social Science at Northwestern University Feinberg School of Medicine in Chicago discusses his findings on the cost effectiveness of quality of life assessments.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Related Content
Janet Abrahm, MD, FACP, FAAHPM, of Dana-Farber Cancer Institute
May 27th 2024

Non-Pharmacologic Therapies for Pain Management in Patients With Cancer: Opportunities and Challenges

Dizon Discusses Elements of Sexual Health in Gynecologic Cancer
August 6th 2020

Dizon Discusses Elements of Sexual Health in Gynecologic Cancer

doctor-adobe.stock
April 2nd 2024

A Medical Oncologist’s Insights on Cannabis Use in the Care of Patients With Hematologic Malignancies

Integrating Nutrition Into the Continuum of Cancer Care
June 18th 2020

Integrating Nutrition Into the Continuum of Cancer Care

FDA
March 5th 2024

FDA Approves 2 Denosumab Biosimilars for All Reference Medicine Indications

Noa Shelach, PhD, of Lutris Pharma
February 28th 2024

FDA Grants Orphan Drug Designation to LUT014 for EGFR Inhibitor–Induced Rash